Evidence map›Paper›PMID 42686876›Full record

Articlenpj drug discovery2026

Pushing the boundaries of virtual screening scale of combinatorial spaces with the V-SYNTHES approach.

Mykola Protopopov, Olha Semenenko, Maryna Vasylchuk, Anastasiia V Sadybekov, Arman A Sadybekov, Kateryna Horbatok, Oleksii Hrabovskyi, Anna Kapeliukha, Antonina Nazarova, Dmytro Radchenko and 2 more

Abstract read
In one paragraph

Article in npj drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mykola ProtopopovChemspace LLC, Kyiv, Ukraine.
Olha SemenenkoChemspace LLC, Kyiv, Ukraine.
Maryna VasylchukChemspace LLC, Kyiv, Ukraine.
Anastasiia V SadybekovDepartment of Quantitative and Computational Biology, University of Southern California, Los Angeles, CA, USA.
Arman A SadybekovDepartment of Quantitative and Computational Biology, University of Southern California, Los Angeles, CA, USA.
Kateryna HorbatokChemspace LLC, Kyiv, Ukraine.
Oleksii HrabovskyiChemspace LLC, Kyiv, Ukraine.
Anna KapeliukhaChemspace LLC, Kyiv, Ukraine.
Antonina NazarovaDepartment of Quantitative and Computational Biology, University of Southern California, Los Angeles, CA, USA.
Dmytro RadchenkoEnamine Ltd., Kyiv, Ukraine.
Vsevolod KatritchDepartment of Quantitative and Computational Biology, University of Southern California, Los Angeles, CA, USA. katritch@usc.edu.
Olga TarkhanovaChemspace LLC, Kyiv, Ukraine. o.tarkhanova@chem-space.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Computational screening of giga-scale chemical spaces opens a cost-effective path to high-quality hit identification, providing entry points for drug discovery. As these on-demand spaces grow and successful applications multiply, rigorous blind benchmarks like CACHE Challenges provide important performance metrics for computational tools. Here, we report the first application of the V-SYNTHES2 synthon-based screening approach to the 173-billion-compound Enamine xREAL Space, a 16-fold expansion beyond its previous benchmarks, demonstrating near-linear computational scaling with only a 10-15% increase in cost relative to the 11-billion-compound REAL Space. We applied this workflow in CACHE Challenge #2, targeting the RNA-binding site of NSP13 (SARS-CoV-2), and CACHE Challenge #4, targeting the tyrosine kinase-binding domain of CBLB, both pockets lacking established pharmacology and representing extreme hit-finding challenges. Under blinded, independently validated conditions, V-SYNTHES2 ranked among the top-performing submissions: the 8% hit rate for NSP13 exceeded the field average of 2.3% and placed the approach among the top three workflows, while for CBLB, one compound meeting predefined hit criteria was identified. These results demonstrate that V-SYNTHES2 maintains robust performance at giga-scale on ligand-depleted targets, precisely the conditions where data-driven approaches would face fundamental limitations, and establish a quantitative performance baseline for synthon-based screening of hundred-billion-compound chemical spaces.

Identifiers

PMID42686876
PMCPMC13538404

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.